Emergence of Covid-19 and High Prevalence of Congenital Heart Disease in Infants to Augment Growth of Fetal and Neonatal Monitoring Market

 

Fetal and Neonatal Monitoring Market


Fetal and neonatal monitoring is a technique of monitoring your newborn's heart and lungs before, during, and after he/she was born. Normally the mother passes all of her body functions to the baby via vaginal deliveries or breastfeeding. A monitor is inserted into the birth canal to detect any irregularities in breathing, heartbeat, or pumping. These monitors are also used in early detection of any problems associated with your unborn baby such as congenital heart disease, breathing difficulties, or infections.

Market Dynamics

High prevalence of congenital heart disease in infants is expected to propel growth of the fetal and neonatal monitoring market. For instance, according to the study, Prevalence, profile, and pattern of congenital heart disease in Central India: A prospective, observational study (published in May 2018), the prevalence of congenital heart disease (CHD) was 10.13/1000 live births. Moreover, emergence of Covid-19 is also expected to aid in growth of the market. For instance, in July 2020, Koninklijke Philips N.V. launched Avalon CL Fetal and Maternal Pod and Patch capable of providing “continuous non-invasive monitoring” of important vital signs such as maternal heart rate, fetal heart rate, and uterine activity.

High rate of maternal mortality in emerging economies is expected to offer lucrative growth opportunities for players in the fetal and neonatal monitoring market. For instance, according to Maternal Mortality: 1990 to 2015 Estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division, Sub-Saharan Africa recorded the highest ratio or maternal mortality, at 555 per 100, 000 live births, from 1990 to 2015. Moreover, the United Nations is focused on achieving the Sustainable Development Goals 2015 - 2030 global maternal mortality ratio target of less than 70 per 100 000 live births.

Among regions, North America is expected to witness significant growth in the fetal and neonatal monitoring market, owing to increasing preterm birth rate in the U.S. For instance, according to March of Dimes 2019 report card, the preterm birth rate in the U.S. reached 10.02% in 2018 from 9.63% in 2015.

Competitive Analysis

Major players operating in the fetal and neonatal monitoring market include, Becton, Dickinson and Company, Fujifilm SonoSite Inc., Medtronic Plc, Dragerwerk AG & Co. KGAA, Cooper Surgical, Getinge AB, MindChild Medical, Inc., Natus Medical Incorporated, GE Healthcare, Siemens Healthcare GmbH, ArjoHuntleigh, Inc., Neoventa Medical, Koninklijke Philips N.V., Analogic Corporation, Spacelabs Healthcare Inc., Smiths Medical, and Masimo.

Major players operating in the fetal and neonatal monitoring market are focused on adopting partnership strategies to enhance their market share. For instance, in April 2019, Henry Schein Medical, the U.S. Medical business of Henry Schein, Inc., and MindChild Medical, Inc. signed an exclusive distribution and supply agreement for the MERIDIAN M110 Fetal Monitoring System.

Comments

Post a Comment

Popular posts from this blog

The Emergence of COVID-19 to Augment Growth of the Outsourced Drug Discovery Market

Image
  With billions of dollars in research and development costs, pharmaceutical companies around the world are always looking for new ways to address their production processes in a cost-effective manner. One way to achieve this is through outsourcing drug discovery and development services. This type of service refers to the collaboration between small and large biotech and biotechnology companies to conduct research and development activities aimed at finding better solutions to the company's core chemical concerns. Outsourcing of these drug discovery services has enabled established pharmaceutical and biotechnology companies to focus on the development of new products that can bring about significant therapeutic change and provide tangible advantages to the company's shareholders. Contract research organizations manage almost all aspects of drug discovery. Market Dynamics I ncreasing demand for outsourcing analytical testing and clinical trial services, growing R&D ex
Read more

Otoscope Market Is Gaining Major Traction with Industry Leader Otonexus Medical Technologies Introducing Ultrasound Sensor, Which Aids Middle-Ear Infection Diagnosis

Image
  An otoscope or auricular ear picker is a simple health care tool that is used to inspect the outer ear. Many health care professionals utilize otoscopes to examine ear infections during routine check-ups and to also screen for serious ear disorders. An otoscope possibly provides a more detailed view of the external ear canal and/or ear drum or eardrum. Otoscope or also referred to as auriscope is mainly used to look into eyes. The demand for these medical devices has been on a rise in the recent past. This is typically due to the fact that there is a high burden of ENT-related diseases across the globe. As per the World Health Organization (WHO), by 2050, around 2.5 billion people are estimated to have some degree of hearing loss worldwide. Similarly, there is a heavy burden of sinusitis cases. As per the Sinusitis & Allergy Wellness Center, around 30 million adults in the U.S. are impacted with sinusitis annually. Such a high prevalence of ENT disorders has accelerated the deman
Read more

The Number of Cancer Survivors Is Projected To Increase to 22.2 Million By 2030 Fostering Oncology Drug Pipeline Analysis Market

Image
  North America is estimated to dominate the global oncology drug pipeline analysis market in the near future and this is attributed to the high prevalence of cancer and increasing launch of various novel drugs with improved efficacy. According to the National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors in the United States. The number of cancer survivors is projected to increase to 22.2 million by 2030. The oncology field is experiencing significant growth and this is attributed to the increasing development of various novel therapies for the treatment of cancer. For instance, in February 2021, Rhizen Pharmaceuticals AG, a clinical-stage, oncology-focused biopharma company, with a 50% stake owned by Alembic Pharmaceuticals and the rest by its Indian CEO Swaroop Vakkalanka, has announced that its the novel, next-generation PI3K-delta inhibitor Umbralisib (Ukoniq) has secured U.S. FDA accelerated approval for the treatment of blood cance
Read more